Gsk (GLAXF) Payables (2009 - 2026)

Gsk's Payables history runs 18 years deep, the most recent figure standing at -$26.1 billion for Q1 2026.

• In Q1 2026, Payables fell 35.03% year-over-year to -$26.1 billion; the TTM figure through Mar 2026 stood at -$26.1 billion (down 35.03% YoY), while the FY2025 annual figure was -$24.3 billion, down 207.28% from the prior year.
• Payables was -$26.1 billion for Q1 2026 at Gsk, down from -$24.5 billion in the prior quarter.
• In the past five years, Payables ranged from a high of $23.7 billion in Q4 2022 to a low of -$26.1 billion in Q1 2026.
• Historically, Payables has averaged -$12.7 billion across 5 years, with a median of -$19.9 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Payables surged 78.55% in 2022, then sank 289.45% in 2023.
• A 5-year view of Payables shows it stood at $23.7 billion in 2022, then decreased by 2.34% to $23.2 billion in 2023, then slipped by 1.98% to $22.7 billion in 2024, then slumped by 207.79% to -$24.5 billion in 2025, then dropped by 6.79% to -$26.1 billion in 2026.
• The last three Payables figures came in at -$26.1 billion (Q1 2026), -$24.5 billion (Q4 2025), and -$21.9 billion (Q3 2025), per Business Quant data.